BackIllumina Overview
Illumina Inc

Illumina Target Price

Analysts' average 12-month price target for Illumina is $240.

Get informed when a big investor buys or sells

+ Follow

Share Price

$207.01

Average Target Price

$244.7118.2% upside

14 analysts in the last 4 months

High: $305 | Low: $160

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-23Stephens$27532.8% upsideOpen
2026-10-19Canaccord Genuity$30044.9% upsideOpen
2026-10-07Barclays$2003.4% downsideOpen
2026-10-01GuggenheimSubbu Nambi$30547.3% upsideOpen
2026-09-29Leerink Partners$30044.9% upsideOpen
2026-09-28Piper SandlerDavid Westenberg$30547.3% upsideOpen
2026-09-09UBS$26025.6% upsideOpen
2026-09-03Argus Research$23513.5% upsideOpen
2026-08-03Canaccord Genuity$2051% downsideOpen
2026-07-31RBC Capital$23011.1% upsideOpen
2026-07-31Bernstein$2153.9% upsideOpen
2026-07-31Guggenheim$2269.2% upsideOpen
2026-07-31Barclays$16022.7% downsideOpen
2026-07-17Leerink PartnersPuneet Souda$2101.4% upsideOpen
2026-07-14Canaccord GenuityKyle Mikson$1908.2% downsideOpen
2026-06-29Guggenheim$2003.4% downsideOpen
2026-06-26Bernstein$18510.6% downsideOpen
2026-06-01Guggenheim$18013% downsideOpen
2026-05-14RBC Capital$17017.9% downsideOpen
2026-05-14DaiwaIllumina to Outperform$15525.1% downsideOpen
2026-05-01Canaccord Genuity$14032.4% downsideOpen
2026-05-01Barclays$12241.1% downsideOpen
2026-02-09Piper Sandler$17017.9% downsideOpen
2026-02-06Robert W. BairdCatherine Ramsey Schulte$13733.8% downsideOpen
2026-02-06UBS$13534.8% downsideOpen
2026-02-06Evercore ISI$15027.5% downsideOpen
2026-01-26GuggenheimSubbu Nambi$17017.9% downsideOpen
2026-01-26Canaccord Genuity$15027.5% downsideOpen
2026-01-20Stifel NicolausDaniel Arias$15525.1% downsideOpen
2026-01-05Evercore ISIVijay Kumar$15525.1% downsideOpen
2026-01-05Guggenheim$14430.4% downsideOpen
2025-12-15Barclays$11046.9% downsideOpen
2025-10-31Evercore ISIVijay Kumar$14231.4% downsideOpen
2025-10-31Robert W. Baird$10947.3% downsideOpen
2025-10-31UBS$12042% downsideOpen
2025-10-31Canaccord Genuity$11245.9% downsideOpen
2025-10-31BarclaysLuke Sergott$10051.7% downsideOpen
2025-10-24Robert W. Baird$10549.3% downsideOpen
2025-10-02Barclays$9554.1% downsideOpen
2025-09-02RBC Capital$12440.1% downsideOpen
2025-08-04Morgan Stanley$10549.3% downsideOpen
2025-08-04Stephens$11046.9% downsideOpen
2025-06-24BarclaysLuke Sergott$8558.9% downsideOpen
2025-05-15Piper SandlerDavid Westenberg$18510.6% downsideOpen
2025-03-11Canaccord Genuity$11544.4% downsideOpen
2025-03-05Robert W. Baird$9056.5% downsideOpen
2025-02-28National Bank$10051.7% downsideOpen
2025-02-28HSBC$10051.7% downsideOpen
2025-02-03BarclaysLuke Sergott$13037.2% downsideOpen
2025-01-10BernsteinEve Burstein$14032.4% downsideOpen

Illumina (ILMN) FAQ

Illumina posts a target price of $240. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $240 for ILMN means covering analysts, on average, see the stock 18.2% upside of $207.01 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ILMN's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Illumina's other metric pages and overview cover the third.

Judging Illumina against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $240 here, then scan peer and history charts to see if the gap is persistent.